Invention Grant
- Patent Title: Oxime ether compounds
-
Application No.: US16636662Application Date: 2018-08-08
-
Publication No.: US11059784B2Publication Date: 2021-07-13
- Inventor: Alaric J. Dyckman , Ling Li , T. G. Murali Dhar , Hai-Yun Xiao
- Applicant: BRISTOL-MYERS SQUIBB COMPANY
- Applicant Address: US NJ Princeton
- Assignee: BRISTOL-MYERS SQUIBB COMPANY
- Current Assignee: BRISTOL-MYERS SQUIBB COMPANY
- Current Assignee Address: US NJ Princeton
- Agent Gary Greenblatt
- International Application: PCT/US2018/045690 WO 20180808
- International Announcement: WO2019/032631 WO 20190214
- Main IPC: C07D213/53
- IPC: C07D213/53 ; C07D207/12 ; A61P37/06 ; C07D211/96 ; C07D211/40

Abstract:
Disclosed are compounds of Formula (I): (I) or a salt thereof, wherein: X is CH or N; Y is CH or N; R1 is —OH or —OP(O)(OH)2; L is —CR3═N—O—CRaRa— or CRaR—O—N═CR3; L2 is a bond, —C(O)—, or S(O)2—; and R2, R3, Ra, m, and n are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.
Public/Granted literature
- US20210147361A1 OXIME ETHER COMPOUNDS Public/Granted day:2021-05-20
Information query
IPC分类: